Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer

Anania, Maria Chiara; Marco, Tiziana Di; Mazzoni, Mara; Greco, Angela

doi:10.3390/cancers12010129

Cited by 7 publications

(5 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers have demonstrated that the deregulation of lncRNAs affects cancer growth and metastasis 20 . CASC2 has been shown to suppress many types of tumor 21 .…”

Section: Discussionmentioning

confidence: 99%

CASC2 inhibits the growth, migration, and invasion of thyroid cancer cells through sponging miR‐18a‐5p/FIH1 axis

Liu

Gao

et al. 2020

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Long noncoding RNA (lncRNA) Cancer Susceptibility 2 (CASC2) has been proved to contribute to the development of cancers. However, the mechanism behind the action of CASC2 in thyroid cancer is not quite clear. We demonstrated that CASC2 was downregulated in thyroid cancer. We noted that CASC2 overexpression restrained the growth, migration, and invasion of thyroid cancer cells, whereas CASC2 depletion caused opposite trends. Bioinformatics analysis predicted that hypoxia inducible factor 1 subunit alpha inhibitor (FIH-1) was potentially targeted by miR-18a-5p, which was confirmed by luciferase reporter assay. Upregulation of FIH-1 abrogated the promotive effect of miR-18a-5p on the growth and invasion of thyroid cancer cells. In addition, CASC2 serves as a competing endogenous RNA (ceRNA) and a ''sponge'' for miR-18a-5p, thereby regulating the expression of FIH-1. These data elucidated the CASC2/miR-18a-5p ceRNA network in thyroid cancer pathogenesis.

show abstract

“…Researchers have demonstrated that the deregulation of lncRNAs affects cancer growth and metastasis 20 . CASC2 has been shown to suppress many types of tumor 21 .…”

Section: Discussionmentioning

confidence: 99%

CASC2 inhibits the growth, migration, and invasion of thyroid cancer cells through sponging miR‐18a‐5p/FIH1 axis

Liu

Gao

et al. 2020

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…As described, aberration of activated Wnt/β-catenin signaling pathway enhances the transcriptional activity of CCND1 and increases nuclear accumulation of cyclin D1. Activation of MAPK and PI3K/AKT pathways, which is usually induced by BRAF and RAS family mutations, are the two most fundamental causative factors of PTC ( 121 , 122 ). The RAS – MAPK pathway regulates cell cycle entry by upregulating cyclin D1 expression in PTC cells ( 56 ).…”

Section: Cyclin D1-targeted Treatmentsmentioning

confidence: 99%

Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma

et al. 2023

View full text Add to dashboard Cite

Cyclin D1 functions as a mitogenic sensor that specifically binds to CDK4/6, thereby integrating external mitogenic inputs and cell cycle progression. Cyclin D1 interacts with transcription factors and regulates various important cellular processes, including differentiation, proliferation, apoptosis, and DNA repair. Therefore, its dysregulation contributes to carcinogenesis. Cyclin D1 is highly expressed in papillary thyroid carcinoma (PTC). However, the particular cellular mechanisms through which abnormal cyclin D1 expression causes PTC are poorly understood. Unveiling the regulatory mechanisms of cyclin D1 and its function in PTC may help determine clinically effective strategies, and open up better opportunities for further research, leading to the development of novel PTC regimens that are clinically effective. This review explores the mechanisms underlying cyclin D1 overexpression in PTC. Furthermore, we discuss the role of cyclin D1 in PTC tumorigenesis via its interactions with other regulatory elements. Finally, recent progress in the development of therapeutic options targeting cyclin D1 in PTC is examined and summarized.

show abstract

“…Finally, several TAAs were implicated in thyroid neoplasia in a fully bottom-up setting. In such a way, we hypothesized that cyclin D1 CCND1, a critical positive regulator of the cell cycle that was extensively implicated in the pathogenesis and tissue-based diagnostics of PTC (reviewed in [ 145 ]) but was also described as a target of TAA-AAbs in other cancers [ 146 , 147 ], may also trigger the diagnostically relevant autoantibody response in thyroid tumors. The CCND1-AAbs were ultimately found in 4/25 (16%) of patients with classical PTC but were completely absent from all classes of FPT and healthy controls ( Figure 2 ) [ 148 ].…”

Section: The Tumor-associated Antigens (Taas) and Their Cognate Autoa...mentioning

confidence: 99%

The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges

Belousov

2022

Biomedicines

View full text Add to dashboard Cite

The Autoantibodies targeting Tumor-Associated Antigens (TAA-AAbs) emerge as a result of a variety of tumor-related immunogenic stimuli and may be regarded as the eyewitnesses to the anti-tumor immune response. TAA-AAbs may be readily detected in peripheral blood to unveil the presence of a particular TAA-expressing tumor, and a fair number of TAAs eliciting the tumor-associated autoantibody response have been identified. The potential of TAA-AAbs as tumor biomarkers has been extensively studied in many human malignancies with a major influence on public health; however, tumors of the endocrine system, and, in particular, the well-differentiated follicular cell-derived thyroid neoplasms, remain understudied in this context. This review provides a detailed perspective on and legitimate rationales for the potential use of TAA-AAbs in thyroid neoplasia, with particular reference to the already established diagnostic implications of the TAA-AAbs in human cancer, to the windows for improvement and diagnostic niches in the current workup strategies in nodular thyroid disease and differentiated thyroid cancer that TAA-AAbs may successfully occupy, as well as to the proof-of-concept studies demonstrating the usefulness of TAA-AAbs in thyroid oncology, particularly for the pre-surgical discrimination between tumors of different malignant potential in the context of the indeterminate results of the fine-needle aspiration cytology.

show abstract

Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer

Cited by 7 publications

References 150 publications

CASC2 inhibits the growth, migration, and invasion of thyroid cancer cells through sponging miR‐18a‐5p/FIH1 axis

CASC2 inhibits the growth, migration, and invasion of thyroid cancer cells through sponging miR‐18a‐5p/FIH1 axis

Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma

The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges

Contact Info

Product

Resources

About